Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

BACKGROUND: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB. METHODS: We nested a two-period, fixed-order pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Turkova, Anna, Waalewijn, Hylke, Chan, Man K, Bollen, Pauline D J, Bwakura-Dangarembizi, Mutsa F, Kekitiinwa, Adeodata R, Cotton, Mark F, Lugemwa, Abbas, Variava, Ebrahim, Ahimbisibwe, Grace Miriam, Srirompotong, Ussanee, Mumbiro, Vivian, Amuge, Pauline, Zuidewind, Peter, Ali, Shabinah, Kityo, Cissy M, Archary, Moherndran, Ferrand, Rashida A, Violari, Avy, Gibb, Diana M, Burger, David M, Ford, Deborah, Colbers, Angela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630157/
https://www.ncbi.nlm.nih.gov/pubmed/35868341
http://dx.doi.org/10.1016/S2352-3018(22)00160-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9630157/
https://www.ncbi.nlm.nih.gov/pubmed/35868341
http://dx.doi.org/10.1016/S2352-3018(22)00160-6

Ejemplares similares